TY - JOUR
AU - Shen, Jie
AB - INTRODUCTIONBiliary tract cancers (BTC) are a group of low incidence hepatobiliary malignancies that include gallbladder carcinoma (GBC), intrahepatic cholangiocarcinoma (ICC), and extrahepatic cholangiocarcinoma (ECC). Incidence varies by region, with the highest incidence in Southeast Asia.1 Its morbidity and mortality are rising.2,3 Surgery is the only treatment that may eradicate BTC, however, most patients are already advanced at the time of initial diagnosis, thus losing the opportunity for surgery.4 And there is a high rate of recurrence after surgery.5 Almost all patients end up on palliative medication.Based on the ABC‐02 study,6 a chemotherapy regimen of gemcitabine combined with cisplatin (GP) is the standard first‐line treatment for advanced BTC, with a median overall survival (mOS) of approximately 1 year. Other new chemotherapy regimens have been tried, but the improvement in efficacy has not been remarkable and overall survival (OS) remains unsatisfactory.7 Hence, there is a need to explore new treatment methods.ICIs are now widely used in clinical practice, with the most widely used being anti‐programmed cell death 1/ligand 1 (PD‐1/PD‐L1) antibodies. Their regimens in combination with chemotherapy or targeted therapy have been approved for first‐line treatment of various tumors, such as head and neck tumors, lung cancer and renal carcinoma. Anti‐PD‐1/PD‐L1 combination 
TI - Survival benefit and biomarker of PD‐1 inhibitor combination therapy in first‐line of advanced biliary tract cancer: A retrospective study
JF - Cancer Medicine
DO - 10.1002/cam4.6628
DA - 2023-11-01
UR - https://www.deepdyve.com/lp/wiley/survival-benefit-and-biomarker-of-pd-1-inhibitor-combination-therapy-05DO9ZiODx
SP - 20699
EP - 20711
VL - 12
IS - 22
DP - DeepDyve
ER -